Tal Zaks

10.4k citations

51 papers · 6.9k indexed · 5 hit papers · h-index 27

Co-authors: Róbert Langer Xucheng Hou Yizhou Dong Steven A. Rosenberg Nicholas P. Restifo Michael Watson James D. Thompson Mike Smith
Topics: Lung Cancer Treatments and Mutations (12 papers)HER2/EGFR in Cancer Research (11 papers)Immunotherapy and Immune Responses (10 papers)
Cited by: Immunology Oncology Infectious Diseases
Journals: Journal of Clinical Investigation Nature Medicine Journal of Clinical Oncology
Partner nations: United States United Kingdom Israel

In The Last Decade

Tal Zaks

50 papers receiving 6.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lipid nanoparticles for mRNA delivery

2021 2.4k citations Tal Zaks et al. profile →
Endogenous oncogenic K-rasG12D stimulates proliferation and widespread neoplastic and developmental defects

2004 626 citations David A. Tuveson, Alice T. Shaw et al. Cancer Cell profile →
Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses

2017 493 citations Kapil Bahl, Olga Yuzhakov et al. Molecular Therapy profile →
mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials

2019 331 citations Robert Feldman, Rainard Fuhr et al. Vaccine profile →
mRNA vaccine–induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer

2020 313 citations Tal Zaks, Steven A. Rosenberg et al. profile →

Peers

Countries citing papers authored by Tal Zaks

Since Specialization

Citations

This map shows the geographic impact of Tal Zaks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tal Zaks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tal Zaks more than expected).

Fields of papers citing papers by Tal Zaks

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tal Zaks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tal Zaks. The network helps show where Tal Zaks may publish in the future.

Co-authorship network of co-authors of Tal Zaks

This figure shows the co-authorship network connecting the top 25 collaborators of Tal Zaks. A scholar is included among the top collaborators of Tal Zaks based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tal Zaks. Tal Zaks is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clinical Development of mRNA Vaccines: Challenges and Opportunities 2022 ·Current topics in microbiology and immunology ·Allison August,(unknown),Robert Paris,Tal Zaks	8
2	A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus 2021 ·Nature Medicine ·Allison August,Husain Attarwala,Sunny Himansu,(unknown),(unknown),Rolando Pajón,Shu Han,Jean‐Michel Lecerf,Joanne E. Tomassini,Marjie Hard,Leon M. Ptaszek,James E. Crowe,Tal Zaks	118
3	A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults 2020 ·Human Vaccines & Immunotherapeutics ·Antonios O. Aliprantis,Christine A. Shaw,Paul Griffin,Nicholas Farinola,Radha Railkar,(unknown),Wen Liu,Jeffrey R. Sachs,(unknown),Heather Lee,Kara S. Cox,Daniel S. Spellman,Colleen J. Winstead,Igor Smolenov,Eseng Lai,Tal Zaks,Amy S. Espeseth,Lori Panther	111
4	mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trialsbreakdown → 2019 ·Vaccine ·Robert Feldman,Rainard Fuhr,Igor Smolenov,(unknown),Lori Panther,Michael Watson,Joseph J. Senn,Mike Smith,Örn Almarsson,Hari Pujar,Michael E. Laska,James D. Thompson,Tal Zaks,Giuseppe Ciaramella	331
5	Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Virusesbreakdown → 2017 ·Molecular Therapy ·Kapil Bahl,(unknown),Olga Yuzhakov,Alex Bulychev,Luis A. Brito,Kimberly J. Hassett,Michael E. Laska,Mike Smith,Örn Almarsson,James D. Thompson,(unknown),Michael Watson,Tal Zaks,Giuseppe Ciaramella	493
6	Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors 2010 ·Investigational New Drugs ·Matthew D. Galsky,Daniel D. Von Hoff,Marcus A. Neubauer,(unknown),Mark T. Fleming,Yasir M. Nagarwala,Janine Mahoney,Dawn Midwinter,(unknown),Tal Zaks	52
7	Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases 2009 ·Cancer Research ·Fawn Qian,Stefan Engst,Toshihiro Yamaguchi,Peiwen Yu,Kwang‐Ai Won,(unknown),Tracy Lou,Jenny Tan,(unknown),Danny Tam,Julie C. Lougheed,F. Michael Yakes,Frauke Bentzien,Wei Xu,Tal Zaks,Richard Wooster,Joel Greshock,Alison Joly	282
8	Distinct patterns of DNA copy number alterations associate with BRAF mutations in melanomas and melanoma‐derived cell lines 2009 ·Genes Chromosomes and Cancer ·Joel Greshock,Katherine L. Nathanson,(unknown),Maria R. Ward,Meenhard Herlyn,Barbara L. Weber,Tal Zaks	21
9	Genome-wide DNA copy number predictors of lapatinib sensitivity in tumor-derived cell lines 2008 ·Molecular Cancer Therapeutics ·Joel Greshock,Jie Cheng,David W. Rusnak,Anne Marie Martin,Richard Wooster,Tona M. Gilmer,Kwan Lee,Barbara L. Weber,Tal Zaks	18
10	Phase II Study of Predictive Biomarker Profiles for Response Targeting Human Epidermal Growth Factor Receptor 2 (HER-2) in Advanced Inflammatory Breast Cancer With Lapatinib Monotherapy 2008 ·Journal of Clinical Oncology ·Stephen Johnston,Maureen Trudeau,Bella Kaufman,Hamouda Boussen,(unknown),Patricia LoRusso,Donald P. Lombardi,Slim Ben Ahmed,Dennis L. Citrin,Michelle DeSilvio,Jennifer L. Harris,Ron E. Westlund,Vanessa Salazar,Tal Zaks,Neil L. Spector	152
11	Preoperative treatment with pazopanib (GW786034), a multikinase angiogenesis inhibitor in early-stage non-small cell lung cancer (NSCLC): A proof-of-concept phase II study 2008 ·Journal of Clinical Oncology ·Nasser K. Altorki,Michael J. Guarino,(unknown),Harvey I. Pass,(unknown),(unknown),D. Roychowdhury,Tal Zaks,Lone H. Ottesen,David Yankelevitz	28
12	Cancer Cell Lines as Genetic Models of Their Parent Histology: Analyses Based on Array Comparative Genomic Hybridization 2007 ·Cancer Research ·Joel Greshock,Katherine L. Nathanson,Anne‐Marie Martin,Lin Zhang,George Coukos,Barbara Weber,Tal Zaks	56
13	Biomarker analyses of PLK isoforms in breast cancer 2006 ·Cancer Research ·Yan Degenhardt,Katja Remlinger,Joel Greshock,Tal Zaks,Barbara L. Weber,Tona M. Gilmer	1
14	High resolution genomic analysis of sporadic breast cancer using array-based comparative genomic hybridization 2005 ·Breast Cancer Research ·Tara L. Naylor,Joel Greshock,Yan Wang,Theresa A. Colligon,(unknown),(unknown),Tal Zaks,Barbara L. Weber	165
15	Endogenous oncogenic K-rasG12D stimulates proliferation and widespread neoplastic and developmental defectsbreakdown → 2004 ·Cancer Cell ·David A. Tuveson,Alice T. Shaw,Nicholas A. Willis,Daniel P. Silver,Erica L. Jackson,Sandy Chang,Kim L. Mercer,Rebecca Grochow,Hanno Hock,Denise Crowley,Sunil R. Hingorani,Tal Zaks,Catrina E. King,Michael A. Jacobetz,Lifu Wang,Roderick T. Bronson,Stuart H. Orkin,Ronald A. DePinho,Tyler Jacks	626
16	INDUCTION OF PROINFLAMMATORY AND CHEMOKINE GENES BY LIPOPOLYSACCHARIDE AND PACLITAXEL (Taxol™) IN MURINE AND HUMAN BREAST CANCER CELL LINES 2001 ·Cytokine ·Meirav Zaks‐Zilberman,Tal Zaks,Stefanie N. Vogel	88
17	TCR stimulation protects CD8+ T cells from CD95 mediated apoptosis 2001 ·Human Immunology ·Michael Karas,Tal Zaks,Shoshana Yakar,Mark E. Dudley,Derek LeRoith	12
18	T Cell Receptor-induced Activation and Apoptosis In Cycling Human T Cells Occur throughout the Cell Cycle 1999 ·Molecular Biology of the Cell ·Michael Karas,Tal Zaks,Jun‐Li Liu,Derek LeRoith	18
19	Cancer therapy using a self-replicating RNA vaccine 1999 ·Nature Medicine ·Ying Han,Tal Zaks,Rong‐Fu Wang,Kari R. Irvine,Udai S. Kammula,Francesco M. Marincola,Wolfgang W. Leitner,Nicholas P. Restifo	269
20	Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. 1998 ·PubMed ·Tal Zaks,Steven A. Rosenberg	188

About Tal Zaks

Tal Zaks is a scholar working on Oncology, Genetics and Immunology, having authored 51 papers that have together received 6.9k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (12 papers), HER2/EGFR in Cancer Research (11 papers) and Immunotherapy and Immune Responses (10 papers). The work is most often cited by research in Immunology (1.9k citations), Oncology (1.8k citations) and Infectious Diseases (1.2k citations). Tal Zaks has collaborated with scholars based in United States, United Kingdom and Israel. Frequent co-authors include Róbert Langer, Xucheng Hou, Yizhou Dong, Steven A. Rosenberg, Nicholas P. Restifo, Michael Watson, James D. Thompson, Mike Smith, Giuseppe Ciaramella and Örn Almarsson. Their work appears in journals such as Journal of Clinical Investigation, Nature Medicine and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact